<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3495C560-9E14-47AD-8586-ED173A819D4E"><gtr:id>3495C560-9E14-47AD-8586-ED173A819D4E</gtr:id><gtr:name>Medpharm Limited</gtr:name><gtr:address><gtr:line1>UNIT 3 CHANCELLOR COURT , 50 OCCAM ROAD</gtr:line1><gtr:city>SURREY RESEARCH PARK GUILDFORD</gtr:city><gtr:postCode>GU2 7YN</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3495C560-9E14-47AD-8586-ED173A819D4E" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>3495C560-9E14-47AD-8586-ED173A819D4E</gtr:id><gtr:name>Medpharm Limited</gtr:name><gtr:address><gtr:line1>UNIT 3 CHANCELLOR COURT , 50 OCCAM ROAD</gtr:line1><gtr:city>SURREY RESEARCH PARK GUILDFORD</gtr:city><gtr:postCode>GU2 7YN</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100000.0</gtr:offerGrant><gtr:projectCost>188390.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710143"><gtr:id>A085D0B5-16D0-4EFE-A134-8232DFEAAE4E</gtr:id><gtr:title>Development of PsoraMed for the topical methotrexate treatment of psoriasis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710143</gtr:grantReference><gtr:abstractText>Psoriasis is an autoimmune-mediated chronic disease that reportedly affects 2 % of the
world?s population. To date it has been difficult to treat with majority of the successful
treatments being systemically active such as methotrexate (MTX) and acitretin, administered
orally and biologics, administered by injection. All have serious side effects and although
topical treatments have been developed to overcome these issues, none are used when the
condition passes its early stages. MTX has demonstrated excellent efficacy for psoriasis
however oral administration of MTX is associated with side effects such as liver and kidney
disease and gastrointestinal irritation. However, currently there are no approved topical
formulations that contain MTX mainly because it is believed that therapeutic levels of MTX
at the pathological site are hard to achieve with topical administration. Development of a
product that could deliver sufficient levels of MTX to the target site would significantly
reduce systemic toxicity and increase patient compliance by reducing treatment times
associated with current topical medications. A promising novel strategy to enhance skin
permeation is the application of superficial heat in conjunction with chemical enhancers e.g.
MedTherm. Superficial heat in combination with certain chemical enhancers results in
increased drug delivery to the skin without elevated systemic absorption by temporarily
increasing barrier fluidity and drug diffusivity making it easier for the MTX to permeate. The
applied heat also provides a relief to itching associated with the psoriasis, a benefit not offered
by other topical products. As such, the overall objective of this project is to develop a topical
MTX treatment for psoriasis using this novel combination of heat generation and chemical
enhancers. Inevitably, this will contribute to reducing the financial burden to the NHS, as well
as society in the form of ?sick days? taken due to the debilitating condition.</gtr:abstractText><gtr:fund><gtr:end>2013-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710143</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>